Figures
- FIGURE 1
Prevalence and change in the total number of symptoms during and 3 months after infection. The width of lines in the figure are proportional to the flow rate.
- FIGURE 2
Prevalence of symptoms during the infection and at follow-up (79 days later). BW: body weight; HR: heart rate.
- FIGURE 3
Prevalence and change in self-reported health status during and 3 months after the infection. The width of lines in the figure are proportional to the flow rate.
Tables
- TABLE 1
Clinical characteristics of the whole sample and stratified for COVID-19 diagnosis
Whole sample (n=2113) Hospitalised (n=112) Nonhospitalised (confirmed COVID-19) (n=345) Nonhospitalised (symptom-based COVID-19) (n=882) Nonhospitalised (suspected COVID-19) (n=774) p-value Women 1803 (85.3) 78 (69.6) 314 (91.0) 774 (87.8) 637 (82.3) <0.001 Age years 47.0 (39.0–54.0) 53.0 (46.3–60.0) 47.0 (37.0–53.5) 46.0 (38.0–53.0) 47.0 (39.0–54.0) <0.001 BMI kg·m−2 25.2 (22.6–28.8) 26.9 (24.5–30.9) 26.0 (23.2–29.4) 25.0 (22.3–28.7) 24.9 (22.5–28.4) <0.001 Self-reported pre-existing comorbidities None 1293 (61.2) 51 (45.5) 225 (65.2) 523 (59.3) 494 (63.8) 0.007 1 comorbidity 541 (25.6) 40 (35.7) 77 (22.3) 240 (27.2) 184 (23.8) ≥2 comorbidities 279 (13.2) 21 (18.8) 43 (12.5) 119 (13.5) 96 (12.4) Self-reported health status before the onset of symptoms Good 1799 (85.1) 88 (78.6) 316 (91.6) 743 (84.2) 652 (84.2) 0.011 Moderate 301 (14.2) 23 (20.5) 27 (7.8) 134 (15.2) 117 (15.1) Poor 13 (0.6) 1 (0.9) 2 (0.6) 5 (0.6) 5 (0.6) Received health care during/after the onset of symptoms General practitioner 1285 (60.8) 62 (55.4) 191 (55.4) 584 (66.2) 448 (57.9) <0.001 Physiotherapist 432 (20.4) 42 (37.5) 74 (21.4) 214 (24.3) 102 (13.2) <0.001 Medical specialist 366 (17.3) 49 (43.8) 68 (19.7) 153 (17.3) 96 (12.4) <0.001 Psychologist 112 (5.3) 16 (14.3) 23 (6.7) 42 (4.8) 31 (4.0) <0.001 Dietician 78 (3.7) 17 (15.2) 15 (4.3) 34 (3.9) 12 (1.6) <0.001 Nurse 63 (3.0) 16 (14.3) 10 (2.9) 25 (2.8) 12 (1.6) <0.001 Occupational therapist 25 (1.2) 2 (1.8) 5 (1.4) 15 (1.7) 3 (0.4) 0.080 Data are presented as n (%) or median (interquartile range), unless otherwise stated. BMI: body mass index.
- TABLE 2
Symptoms during the infection of the whole sample and stratified for COVID-19 diagnosis
Whole sample (n=2113) Hospitalised (n=112) Nonhospitalised (confirmed COVID-19) (n=345) Nonhospitalised (symptom-based COVID-19) (n=882) Nonhospitalised (suspected COVID-19) (n=774) p-value Number of symptoms 14.0 (11.0–17.0) 14.0 (9.3–17.0) 14.0 (11.0–18.0) 14.0 (11.0–18.0) 13.0 (10.0–17.0) <0.001 Symptoms Fatigue 2006 (94.9) 104 (92.9) 324 (93.9) 847 (96.0) 731 (94.4) 0.226 Dyspnoea 1892 (89.5) 100 (89.3) 300 (87.0) 827 (93.8) 665 (85.9) <0.001 Headache 1605 (76.0) 80 (71.4) 273 (79.1) 682 (77.3) 570 (73.6) 0.097 Chest tightness 1588 (75.2) 68 (60.7) 248 (71.9) 709 (80.4) 563 (72.7) <0.001 Cough 1438 (68.1) 89 (79.5) 235 (68.1) 620 (70.3) 494 (63.8) 0.002 Muscle pain 1367 (64.7) 60 (53.6) 245 (71.0) 578 (65.5) 484 (62.5) 0.003 Sore throat 1309 (61.9) 49 (43.8) 188 (54.5) 564 (63.9) 508 (65.6) <0.001 Increased body temp. (37.0–37.9°C) 1293 (61.2) 44 (39.3) 189 (54.8) 571 (64.7) 489 (63.2) <0.001 Pain between shoulder blades 1289 (61.0) 53 (47.3) 216 (62.6) 584 (66.2) 436 (56.3) <0.001 Pain/burning feeling in lungs 1279 (60.5) 53 (47.3) 178 (51.6) 587 (66.6) 461 (59.6) <0.001 Heart palpitations 1159 (54.9) 44 (39.3) 191 (55.4) 521 (59.1) 403 (52.1) <0.001 Increased resting heart rate 1154 (54.6) 58 (51.8) 199 (57.7) 519 (58.8) 378 (48.8) <0.001 Dizziness 1091 (51.6) 46 (41.1) 171 (49.6) 490 (55.6) 384 (49.6) 0.006 Nose cold 928 (43.9) 38 (33.9) 169 (49.0) 363 (41.2) 358 (46.3) 0.006 Burning feeling in the trachea 927 (43.9) 37 (33.0) 121 (35.1) 428 (48.5) 341 (44.1) <0.001 Fever (≥38.0°C) 903 (42.7) 94 (83.9) 178 (51.6) 380 (43.1) 251 (32.4) <0.001 Ageusia 893 (42.3) 73 (65.2) 218 (63.2) 350 (39.7) 252 (32.6) <0.001 Diarrhoea 869 (41.1) 49 (43.8) 150 (43.5) 374 (42.4) 296 (38.2) 0.225 Anosmia 839 (39.7) 67 (59.8) 223 (64.6) 308 (34.9) 241 (31.1) <0.001 Joint pain 808 (38.2) 37 (33.0) 151 (43.8) 340 (38.5) 280 (36.2) 0.066 Nausea 772 (36.5) 51 (45.5) 124 (35.9) 341 (38.7) 256 (33.1) 0.021 Mucus 764 (36.2) 42 (37.5) 107 (31.0) 328 (37.2) 287 (37.1) 0.193 Sneezing 667 (31.6) 27 (24.1) 123 (35.7) 274 (31.1) 243 (31.4) 0.129 Hot flushes 548 (25.9) 18 (16.1) 90 (26.1) 224 (25.4) 216 (27.9) 0.061 Eye problems 542 (25.7) 20 (17.9) 76 (22.0) 245 (27.8) 201 (26.0) 0.045 Ear pain 459 (21.7) 12 (10.7) 74 (21.4) 210 (23.8) 163 (21.1) 0.015 Sudden loss of body weight 388 (18.4) 42 (37.5) 81 (23.5) 165 (18.7) 100 (12.9) <0.001 Vomiting 191 (9.0) 24 (21.4) 41 (11.9) 76 (8.6) 50 (6.5) <0.001 Red spots on toes/feet 118 (5.6) 9 (8.0) 15 (4.3) 50 (5.7) 44 (5.7) 0.512 Others 623 (29.5) 19 (17.0) 87 (25.2) 284 (32.2) 233 (30.1) 0.002 Data are presented as n (%) or median (interquartile range), unless otherwise stated.
Vol 6 Issue 4
Table of Contents
Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?
